Véronique Leblanc

Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA.

Healthcare Businesswomens Association operates women healthcare associations. The company was founded by Diane Anderson, Peg Dougherty, Millicent Gryczka, Sheila Sinkking and Ruth Smith in 1977 and is headquartered in Fairfield, NJ.

Part of Bausch Health Cos., Inc., Laboratoire Chauvin SAS is a French company that specializes in medicinal chemicals and botanical products. The company is based in Montpellier, France. The CEOs of the company are Eberhard Kühne, William Woodfield, Jean-Christophe Henry.

Taconic Biosciences, Inc. provides research rodents and related products and services. It offers monoclonal antibody production, drug safety testing and other services. The firm also provides contract breeding solutions, animal models, Taconic transgenic exchange, custom model generation, contract research solutions, and research services. The company was founded by Robert K. Phelan in 1949 and is headquartered in Rensselaer, NY.

Synt:em SA researches and manufactures drugs for the treatment of pain and cancer. The company specializes in the discovery and development of Central Nervous System (CNS) medicines and novel therapeutics for the treatment diseases. It was founded in 1995 by Michel Kaczorek and Caroline Roussel and is headquartered in Nîmes, France.

ADEMTECH SA specializes in developing and manufacturing magnetic nanoparticles for diagnostic and scientific research applications. The firm produces magnetic nanoparticles for concentration, separation, purification, microfluidic device integration and identification of molecules and specific cells. The company was founded in 2000 and is headquartered in Pessac, France.

BPIFrance Investissement SAS (BPIfrance Investissement) is the private equity arm and subsidiary of State-owned Banque Publique d'Investissement in France. Formerly known as CDC Entreprises SAS, the firm was established in 1994 to carry out public-interest missions such as employment creation and momentum initiation in the private equity field. In 2013 they became BPIfrance Investissement when CDC Entreprises, FSI and FSI Régions merged. Headquartered in Paris, BPIfrance Investissement invests of behalf of the Government of France, as well as for third parties including FEI-Fonds Européen d'Investissement, BEI-Banque Européenne d'Investissement and BPCE SA. The firm invests directly or indirectly in SMEs and intermediate-sized companies at all stages of their development.

Whether its clients are an insurer, employer, or government organization, Sibley is their best connection to a single source solution to their disability issues. Through connected thinking, it provides fully-integrated solutions to prevent, manage and resolve client injury or illness no matter where their disability issues fall along the healthcare continuum. The company put all the pieces together.

HRA Pharma Development SARL develops medicines and products for women's health and endocrinology. It offers emergency contraception, uterine fibroids, regular contraception, intimate health, genital herpes, and Lysosafe service. The company was founded by André Ulmann in 1996 and is headquartered in Châtillon, France.

Laboratoire HRA Pharma SA manufactures and distributes pharmaceutical products. Its products include contraceptive pills such as the pill of two days later and EllaOne. The company was founded by Andre Ulmann in 1996 and is headquartered in Paris, France.

Part of Sanofi, Sanofi-Aventis Participations SAS is a pharmaceutical company based in Paris, France. The French company manufactures pharmaceuticals. The CEO of the company is Mathias Thibault.

Merck Serono SAS manufactures, develops, and sells pharmaceutical drugs and products. It offers medicines for diseases such as cancer, multiple sclerosis, infertility, endocrine, cardio-metabolic disorders, and psoriasis. The company was founded in 1955 and is headquartered in Lyon, France.

GamaMabs Pharma SA specializes in developing monoclonal antibodies. It offers research and development solutions for biopharmaceutical industry. The company was founded by Jean-Francois Prost and Stephane Degove in June 2013 and is headquartered in Toulouse, France.

CorWave SA develops and manufactures blood pumps. The company was founded in 2011 and is headquartered in Paris, France.

Part of Sanofi, Sanofi AB is a pharmaceutical company based in Stockholm, Sweden. The Swedish company's description states that it is an international pharmaceutical company.

Step Pharma SAS develops drugs for immunosuppressive therapies. The company was founded by Geoffroy de Ribains, Alain Fischer, and Sylvain Latour and is headquartered in Paris, France.

Imcheck Therapeutics SAS operates as a biopharmaceutical company which develops immunotherapeutic anti-cancer strategies for research. The company was founded by Olive Daniel in 2015 and is headquartered in Marseille, France.

LimFlow SA develops and offers medical devices which transformes the treatment of critical limb Ischemi. The firm?s proprietary and CE marked technology is a novel and purely percutaneous therapy for ?no-option? CLI patients. The company was founded by Martin T. Rothman in 2012 and is headquartered in Paris, France.

Cemag SAS is a French company that specializes in research and development of physical and natural sciences. The private company is based in Paris, France.

AlgoTherapeutix SAS is a clinical-stage biotechnology company based in Suresnes, France. The French company is focused on developing targeted, first-in-class therapeutics for peripheral neuropathic pain. Its lead asset, ATX01, is a proprietary topical formulation of amitriptyline that targets the signaling pathways involved in the regulation of pain by inhibiting specific nociceptive sodium channel receptors. The company is currently recruiting patients for a phase II clinical trial of 240 patients for chemotherapy-induced neuropathic pain and a phase II proof of concept trial for erythromelalgia. AlgoTherapeutix has secured FDA fast track development status and orphan drug designation in both the US and EU. AlgoTherapeutix has raised EUR 35 million to date and has a consortium of investors, including Relyens Innovation Santé/Turenne Capital, UI Investissement, and angel investors. The company was founded in 2018 by Olivier Jean Bohuon and Stéphane Thiroloix, with Stéphane Thiroloix serving as the CEO since 2018.